title: Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection.
abstract: A cytotoxic T lymphocyte (CTL) response to the hepatitis C virus (HCV) nucleoprotein residues 88-96 that are the minimal and optimal epitope for human leukocyte antigen (HLA) B44-restricted CTLs was assessed in 27 HLA B44-positive patients with chronic HCV infection. Serum HCV RNA concentration and the amino acid sequence of the residues 81-100 were also determined. Three patients were infected with HCV with uncommon amino acid substitutions within the epitope. One was infected with HCV with an amino acid substitution in the flanking residues of the epitope. To stimulate CTLs in the peripheral blood, 9-mer peptides that corresponded to the residues 88-96 of the individual patients were synthesized and used. Seven of the 27 patients demonstrated a CTL response to the residues 88-96 with specific cytotoxic activities higher than 20%. The CTL activities were significantly higher in patients with a low titer of serum HCV RNA than in those with a high titer of serum HCV RNA (P = .0006). Some of the patients that demonstrated a CTL response to the residues 88-96 also demonstrated a CTL response to a newly identified HLA B44-restricted CTL epitope or a known HLA A11-restricted CTL epitope or both. No apparent association was observed between the CTL response and the stage of disease, or between the CTL response and the grade of necroinflammatory activity. The results suggest that the HLA B44-restricted CTLs together with other HCV-specific CTLs may inhibit the outgrowth of HCV and that high-titer infection with HCV may suppress the CTL responses.
authors.affiliation: Hepatology Division, Jichi Medical School, Tochigi, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Hiroishi
authors.forename: H
authors.initials: H
authors.lastname: Kita
authors.forename: M
authors.initials: M
authors.lastname: Kojima
authors.forename: H
authors.initials: H
authors.lastname: Okamoto
authors.forename: T
authors.initials: T
authors.lastname: Moriyama
authors.forename: T
authors.initials: T
authors.lastname: Kaneko
authors.forename: T
authors.initials: T
authors.lastname: Ishikawa
authors.forename: S
authors.initials: S
authors.lastname: Ohnishi
authors.forename: T
authors.initials: T
authors.lastname: Aikawa
authors.forename: N
authors.initials: N
authors.lastname: Tanaka
authors.forename: Y
authors.initials: Y
authors.lastname: Yazaki
authors.forename: K
authors.initials: K
authors.lastname: Mitamura
authors.forename: M
authors.initials: M
authors.lastname: Imawari
mesh_terms: D000328:Adult; D000368:Aged; D000939:Epitopes / Q000276:immunology; D005260:Female; D005838:Genotype; D015235:HLA-B Antigens / Q000276:immunology*; D059948:HLA-B44 Antigen; D006526:Hepatitis C / Q000235:genetics / Q000276:immunology* / Q000821:virology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000032:analysis; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
chemical_list: D000939:Epitopes; D015235:HLA-B Antigens; D059948:HLA-B44 Antigen; D012367:RNA, Viral